We tested 12 PDF generation APIs across 14 rendering checks, comparing HTML-to-PDF accuracy, speed, file sizes, and fillable ...

Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial designs the FDA had already questioned, including response criteria the agency said were not consistent ...

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded ...

Disclosure Under Scrutiny: Replimune's SEC filings warned generally that RP1 might not win approval, yet allegedly omitted that the FDA had already told the Company its study design concerns were ...

Check out the companies making the biggest moves premarket: Replimune Group — Shares were up over 130% for the clinical-stage biotechnology company after a Food and Drug Administration advisory panel ...

Replimune (REPL) shares more than doubled in post-market trading on Thursday after the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted in favor of the company’s lead asset, RP1.

A massive malvertising campaign is using fake Solana, Luno, and TradingView webpages with malicious JavaScript that instructs browsers to assemble malware directly in memory. The operation has been ...

JPMorgan analyst Anupam Rama upgraded Replimune Group (NASDAQ: REPL) from Underweight to Neutral with a price target of $8.00.The analyst ... This is a premium only article. To continue reading this ...

Biggest deals of the year. 30-day money-back guarantee. Limited time deals. 24/7 support. Don't miss out Biggest deals of the year 30-day money-back guarantee Limited time deals 24/7 support Don't ...

This project is a proof-of-concept that runs a JavaScript engine inside a web browser by compiling it to WebAssembly. The engine is Goja — a pure-Go implementation of ECMAScript 5.1 — and the ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...